NEW YORK (GenomeWeb News) – Silicon Valley Biosystems and the Mayo Clinic announced late on Monday a deal aimed at improving "accessibility and clinical utility of next-generation sequencing for patients."

The deal brings together SV Bio's genome interpretation tools and Mayo's genome reference library. Under its terms, SV Bio will provide clinical genome interpretation services and clinical decision support interfaces to Mayo. Mayo's Center for Individualized Medicine will provide clinical and laboratory expertise and support.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.